Trial Profile
A prospective, single-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Meril Life Sciences
- 11 Apr 2017 New trial record